MedTrace Logo

Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

NCT03019887 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2021-09-09

Study results available
· View outcomes & findings →

Summary

To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.

Conditions

  • Schizophrenia Relapse

Interventions

DRUG

reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine

Sponsors & Collaborators

  • Juntendo University

    lead OTHER

Principal Investigators

  • Takahashi Tadashi · Okada hospital

  • Mikiro Saito · Okada hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2017-01-31
Completion
2017-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019887 on ClinicalTrials.gov